The influence of oxo-bridged binuclear gold(III) complexes on Na/K-ATPase activity: a joint experimental and theoretical approach
Само за регистроване кориснике
Čolović, Mirjana B.
Janjić, Goran V.
Krstić, Danijela Z.
Vasić, Vesna M.
Чланак у часопису
МетаподациПриказ свих података о документу
The in vitro effects of oxo-bridged binuclear gold(III) complexes, i.e., [(bipy2Me)(2)Au-2(mu-O)(2)][PF6](2) (Auoxo6), Au-2[(bipydmb-H)(2)(mu-O)][PF6] (Au(2)bipyC) and [Au-2(phen(2Me))(2)(mu-O)(2)](PF6)(2) (Au(2)phen) on Na/K-ATPase, purified from the porcine cerebral cortex, were investigated. All three studied gold complexes inhibited the enzyme activity in a concentration-dependent manner achieving IC50 values in the low micromolar range. Kinetic analysis suggested an uncompetitive mode of inhibition for Auoxo6 and Au(2)bipyC, and a mixed type one for Au(2)phen. Docking studies indicated that the inhibitory actions of all tested complexes are related to E2-P enzyme conformation binding to ion channel and intracellular part between N and P sub-domain. In addition, Au(2)phen was able to inhibit the enzyme by interacting with its extracellular part as well. Toxic effects of the gold(III) complexes were evaluated in vitro by following lactate dehydrogenase activity in rat brain synaptos...omes and incidence of micronuclei and cytokinesis-block proliferation index in cultivated human lymphocytes. All investigated complexes turned out to induce cytogenetic damage consisting of a significant decrease in cell proliferation and an increase in micronuclei in a dose-dependent manner. On the other hand, lactate dehydrogenase activity, an indicator of membrane integrity/viability, was not affected by Auoxo6 and Au(2)bipyC, while Au(2)phen slightly modified its activity.
Кључне речи:Binuclear gold(III) complexes / Na/K-ATPase / Inhibition / Docking studies / Cytotoxicity / Genotoxicity
Извор:Journal of Biological Inorganic Chemistry, 2017, 22, 6, 819-832
- Истраживања интеракција ензима са токсичним и фармаколошки активним молекулима (RS-172023)
- Beneficentia Stiftung (Vaduz), ITT (Istituto Toscano Tumori), Fondazione Cassa Risparmio Firenze (CRF), AIRC [IG-16049], AIRC-FIRC (Fondazione Italiana per la Ricerca sul Cancro)